Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622831 | 1.00 | SMARCA4 (0.34) | SMARCA4PBRM1 | |
| SCHEMBL17893716 | 0.88 | SMARCA4 (0.31) | SMARCA4 | |
| SCHEMBL21990761 | 0.88 | SMARCA4 (0.33) | SMARCA4PBRM1 | |
| SCHEMBL28152878 | 0.88 | SMARCA4 (0.33) | SMARCA4PBRM1 | |
| SCHEMBL710471 | 0.88 | SMARCA4 (0.31) | SMARCA4 | |
| SCHEMBL710472 | 0.88 | SMARCA4 (0.31) | SMARCA4 | |
| SCHEMBL4052256 | 0.80 | CYP2D6 (0.31) | — | |
| SCHEMBL4052259 | 0.80 | CYP2D6 (0.31) | — | |
| SCHEMBL24417745 | 0.79 | USP2 (0.43) | — | |
| SCHEMBL1621681 | 0.79 | USP2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| CN-101652367-A | Pyrimido [4, 5-D ] azepine derivatives as 5-HT 2C agonists | PFIZER LTD GB | 2010-02-17 | — | — | CN | disclosed |
| EP-2139896-A1 | PYRIMIDO [4, 5-D]AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | Pfizer Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008117169-A1 | PYRIMIDO [4, 5-D] AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | PFIZER LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | HTR2C, HTR2A, HTR5A | SMARCA4 3402/4885PBRM1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.